Goldman Sachs Group Inc Infla Rx N.V. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Infla Rx N.V. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 82,200 shares of IFRX stock, worth $207,144. This represents 0.0% of its overall portfolio holdings.
Number of Shares
82,200Holding current value
$207,144% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding IFRX
# of Institutions
29Shares Held
12.9MCall Options Held
19.3KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY5.73MShares$14.4 Million0.35% of portfolio
-
683 Capital Management, LLC New York, NY2.07MShares$5.22 Million0.29% of portfolio
-
Eversept Partners, LP New York, NY1.62MShares$4.09 Million0.2% of portfolio
-
Ubs Oconnor LLC Chicago, IL798KShares$2.01 Million0.08% of portfolio
-
Ikarian Capital, LLC Dallas, TX705KShares$1.78 Million0.19% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $111M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...